PDE4 Inhibitor GI Delivery for Localized Intestinal Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for delivering therapeutic drugs to specific locations in the gastrointestinal (GI) tract, particularly the small intestine and large intestine, face challenges such as unpredictable release due to variable physiological conditions, high systemic exposure, and instability of drugs, especially for biologics like monoclonal antibodies, leading to aggregation and poor stability.
Innovation Solution
The development of ingestible devices with autonomous release mechanisms that localize and deliver therapeutic drugs, including PDE4 inhibitors, to specific sites in the GI tract based on anatomical markers, avoiding reliance on pH or bacterial activity, and allowing for flexible dosing and stable drug delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional oral delivery is used, then convenience of administration is improved, but systemic exposure and harmful side effects increase
Solution Approach 1:
The GI tract is segmented into different regions (stomach, small intestine, large intestine) with distinct release mechanisms. The device uses pH-sensitive components to segment the release process, allowing different drugs to be released at different locations based on the local pH environment, thereby achieving localized delivery while maintaining oral administration convenience
Solution Approach 2:
The device employs local quality differentiation by using pH-sensitive polymers and enzymes that are active only in specific GI tract regions. The formulation is designed to remain stable in the stomach (low pH) and release drugs in the small intestine or large intestine (higher pH), creating localized therapeutic effect while avoiding systemic exposure
2Ease of operation
If traditional oral delivery is used, then ease of administration is improved, but drug stability deteriorates due to harsh chemical and enzymatic conditions
Solution Approach 1:
The device performs preliminary protection by coating drugs with pH-sensitive polymers and protective matrices before administration. This preliminary action shields the drugs from harsh stomach acid and enzymes during transit, and the release is triggered only when the device reaches the appropriate GI region with favorable pH conditions, ensuring drug stability throughout the journey
Solution Approach 2:
The device uses pH-sensitive polymers and enzymatic components as intermediaries between the drug and the harsh GI environment. These intermediaries act as protective barriers that prevent direct contact between unstable drugs and harmful chemical/enzymatic conditions, while still allowing controlled release when pH or enzyme conditions become favorable
3Quantity of substance
If therapeutic drugs are dispensed to specified locations in the small or large intestine, then bioavailability at disease site increases, but device complexity increases
Solution Approach 1:
The device achieves self-service by utilizing the body's own pH gradients and enzymatic environments as triggering mechanisms. The pH-sensitive polymers automatically respond to local pH changes, and enzymatic components are activated by specific gut enzymes, eliminating the need for external sensors, motors, or control systems while still achieving precise location-specific delivery
Solution Approach 2:
The device exploits parameter changes in the GI tract, specifically pH transitions from acidic stomach to neutral/small intestine to alkaline large intestine. By designing release mechanisms that respond to these natural parameter changes, the system achieves location-specific delivery using simple, passive triggers rather than complex active control systems
4Quantity of substance
If pH-dependent release mechanisms are used, then localized delivery is improved, but reliability deteriorates due to variable physiological conditions
Solution Approach 1:
The device uses composite materials combining pH-sensitive polymers with enzymatic components and protective matrices. This composite structure provides redundant release triggers - pH changes provide one mechanism while enzymatic activation provides another - ensuring reliable delivery even when physiological conditions vary between individuals
Solution Approach 2:
The device incorporates beforehand cushioning by including protective matrices and stabilizing excipients that prevent premature release and maintain formulation integrity under variable pH and enzymatic conditions. This cushioning ensures consistent release behavior across different individuals and physiological states
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances drug bioavailability at the disease site, reduces systemic exposure, and improves safety and efficacy by maintaining drug stability and enabling targeted delivery to inflamed tissues, thus providing more effective treatment regimens for GI disorders.
Implementation Method 1
PDE4 catalyzes the breakdown of 3,5'-cyclic adenosine monophosphate (cAMP). Inhibition of PDE4 leads to increased intracellular levels of cAMP
Implementation Method 2
The development of ingestible devices with autonomous release mechanisms that localize and deliver therapeutic drugs, including PDE4 inhibitors, to specific sites in the GI tract
Data Source
AI summary
This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a PDE4 inhibitor.